Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antony Loebel

Showing results (31-40 of 128) with videos related to

Pageof 13
Sort By:
CNS Spectrums|September 14, 2020
Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophreniaMichael Tocco, John W Newcomer, Yongcai Mao, et al.
The American Journal of Managed Care|August 1, 2019
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychoticsDaisy Ng-Mak, Andrew Messali, Ahong Huang, et al.
Current Neuropharmacology|September 29, 2022
Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar DepressionManpreet K Singh, Cynthia Siu, Michael Tocco, et al.
Journal of Child and Adolescent Psychopharmacology|May 6, 2017
Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled StudyRobert Goldman, Antony Loebel, Josephine Cucchiaro, et al.
The Journal of Clinical Psychiatry|August 8, 2018
Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled TrialAnita H Clayton, Joyce Tsai, Yongcai Mao, et al.
Schizophrenia Research|May 15, 2007
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidonePeter F Buckley, Philip D Harvey, Christopher R Bowie, et al.
Journal of Child and Adolescent Psychopharmacology|May 12, 2020
Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: <i>Post Hoc</i> Analysis of a Randomized Placebo-Controlled TrialManpreet K Singh, Andrei Pikalov, Cynthia Siu, et al.
The Journal of Clinical Psychiatry|April 7, 2015
Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trialRoger S McIntyre, Josephine Cucchiaro, Andrei Pikalov, et al.
International Clinical Psychopharmacology|July 22, 2015
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophreniaJonathan M Meyer, Yongcai Mao, Andrei Pikalov, et al.
Brain, Behavior, and Immunity|December 21, 2019
C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trialCharles L Raison, Cynthia Siu, Andrei Pikalov, et al.
Pageof 13

Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
CNS Spectrums|September 14, 2020
Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophreniaMichael Tocco, John W Newcomer, Yongcai Mao, et al.
The American Journal of Managed Care|August 1, 2019
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychoticsDaisy Ng-Mak, Andrew Messali, Ahong Huang, et al.
Current Neuropharmacology|September 29, 2022
Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar DepressionManpreet K Singh, Cynthia Siu, Michael Tocco, et al.
Journal of Child and Adolescent Psychopharmacology|May 6, 2017
Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled StudyRobert Goldman, Antony Loebel, Josephine Cucchiaro, et al.
The Journal of Clinical Psychiatry|August 8, 2018
Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled TrialAnita H Clayton, Joyce Tsai, Yongcai Mao, et al.
Schizophrenia Research|May 15, 2007
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidonePeter F Buckley, Philip D Harvey, Christopher R Bowie, et al.
Journal of Child and Adolescent Psychopharmacology|May 12, 2020
Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: <i>Post Hoc</i> Analysis of a Randomized Placebo-Controlled TrialManpreet K Singh, Andrei Pikalov, Cynthia Siu, et al.
The Journal of Clinical Psychiatry|April 7, 2015
Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trialRoger S McIntyre, Josephine Cucchiaro, Andrei Pikalov, et al.
International Clinical Psychopharmacology|July 22, 2015
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophreniaJonathan M Meyer, Yongcai Mao, Andrei Pikalov, et al.
Brain, Behavior, and Immunity|December 21, 2019
C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trialCharles L Raison, Cynthia Siu, Andrei Pikalov, et al.
Pageof 13